Metropolis Healthcare Reports Strong Growth in Q2 FY2027

Consolidated revenue stood at Rs 4,968.21 million, with a net profit of Rs 753.38 million.

Reader Takeaway: Robust earnings growth and a new interim dividend are offset by the accounting transition of the EQAS division.

What just happened

Metropolis Healthcare released its unaudited financial results for the quarter ended September 30, 2026. The company saw significant year-on-year growth, with consolidated revenue reaching Rs 4,968.21 million compared to Rs 4,291.91 million in the same period last year. Consolidated profit for the period attributable to owners surged to Rs 753.38 million, up from Rs 526.68 million in Q2 FY2026.

Dividend Declaration

The Board of Directors has declared an interim dividend of Re 1 per equity share, having a face value of Rs 2 each. The company has fixed November 9, 2026, as the record date. Shareholders on the register by this date will be eligible for the payout, which is scheduled to be completed within 30 days.

Corporate and Operational Updates

Metropolis has streamlined its operations by transferring its External Quality Assessment Services (EQAS) division to its subsidiary, Metropolis Quality Solutions Private Limited, on a slump sale basis effective August 27, 2026. This business is now categorized under discontinued operations. Additionally, the company granted 1,380 Restricted Stock Units (RSU) and 20,500 Employee Stock Options under its 2025 incentive plans.

What to track next

Investors should monitor the company's margin expansion as it continues its footprint growth across India's competitive diagnostic market. Furthermore, the integration impact of the EQAS division restructuring on core profitability will be a key area of focus for upcoming quarters.